SLC5A2 and diabetes mellitus: These results provide a reasonable basis for SGLT2-i therapy in post-AMI patients with diabetes and/or reduced LVEF to improve outcomes and potentially LVR, although treatment in other post-AMI populations remains under investigation [183].